News

The EORTC intergroup trial 1206:"A randomised phase II study to evaluate the efficacy and safety of chemotherapy vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic,

The MHRA conducted a site-specific inspection in November 2015 to evaluate whether the Group’s existing manufacturing processes and quality management systems had been effectively extended and implemented at

The deal is anticipated to close by the end of this month, earlier than scheduled. Galapagos will receive an upfront payment of $725m, which includes a license fee

The drug is being developed by Ionis Pharmaceuticals and GSK. The companies are also collaborating on the development of IONIS-HBV Rx, a generation 2.0+ antisense HBV drug. Ionis

VAL-083 is a small-molecule chemotherapeutic, which is indicated to treat glioblastoma multiforme (GBM), the most common and deadly cancer that starts within the brain. Under the collaboration, MD

CASI’s China rights to MARQIBO was licensed from its partner Spectrum Pharmaceuticals, Inc. MARQIBO is the first and only liposome-encapsulated vincristine approved and currently marketed in the U.S.

This milestone was reached in 2015 which will be recognised in the financial year 2015. The agreement between Evotec and Janssen for this collaboration became effective on October

The study is designed to support marketing approval of nusinersen in children with spinal muscular atrophy (SMA). Ionis Pharmaceuticals COO Lynne Parshall said: "Achieving our target enrollment number

The clinical trial is expected to begin in the first half of 2016. PLX-R18 is Pluristem’s second cell therapy product cleared for clinical studies by the U.S. FDA.